369 related articles for article (PubMed ID: 24470444)
1. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants.
Bien-Ly N; Yu YJ; Bumbaca D; Elstrott J; Boswell CA; Zhang Y; Luk W; Lu Y; Dennis MS; Weimer RM; Chung I; Watts RJ
J Exp Med; 2014 Feb; 211(2):233-44. PubMed ID: 24470444
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.
Yu YJ; Atwal JK; Zhang Y; Tong RK; Wildsmith KR; Tan C; Bien-Ly N; Hersom M; Maloney JA; Meilandt WJ; Bumbaca D; Gadkar K; Hoyte K; Luk W; Lu Y; Ernst JA; Scearce-Levie K; Couch JA; Dennis MS; Watts RJ
Sci Transl Med; 2014 Nov; 6(261):261ra154. PubMed ID: 25378646
[TBL] [Abstract][Full Text] [Related]
3. Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain.
Gadkar K; Yadav DB; Zuchero JY; Couch JA; Kanodia J; Kenrick MK; Atwal JK; Dennis MS; Prabhu S; Watts RJ; Joseph SB; Ramanujan S
Eur J Pharm Biopharm; 2016 Apr; 101():53-61. PubMed ID: 26820920
[TBL] [Abstract][Full Text] [Related]
4. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.
Yu YJ; Zhang Y; Kenrick M; Hoyte K; Luk W; Lu Y; Atwal J; Elliott JM; Prabhu S; Watts RJ; Dennis MS
Sci Transl Med; 2011 May; 3(84):84ra44. PubMed ID: 21613623
[TBL] [Abstract][Full Text] [Related]
5. Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood-brain barrier in vitro is dependent on its binding affinity.
Haqqani AS; Thom G; Burrell M; Delaney CE; Brunette E; Baumann E; Sodja C; Jezierski A; Webster C; Stanimirovic DB
J Neurochem; 2018 Sep; 146(6):735-752. PubMed ID: 29877588
[TBL] [Abstract][Full Text] [Related]
6. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier.
Couch JA; Yu YJ; Zhang Y; Tarrant JM; Fuji RN; Meilandt WJ; Solanoy H; Tong RK; Hoyte K; Luk W; Lu Y; Gadkar K; Prabhu S; Ordonia BA; Nguyen Q; Lin Y; Lin Z; Balazs M; Scearce-Levie K; Ernst JA; Dennis MS; Watts RJ
Sci Transl Med; 2013 May; 5(183):183ra57, 1-12. PubMed ID: 23636093
[TBL] [Abstract][Full Text] [Related]
7. Prospective Design of Anti-Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain.
Kanodia JS; Gadkar K; Bumbaca D; Zhang Y; Tong RK; Luk W; Hoyte K; Lu Y; Wildsmith KR; Couch JA; Watts RJ; Dennis MS; Ernst JA; Scearce-Levie K; Atwal JK; Ramanujan S; Joseph S
CPT Pharmacometrics Syst Pharmacol; 2016 May; 5(5):283-91. PubMed ID: 27299941
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-β.
Sehlin D; Fang XT; Meier SR; Jansson M; Syvänen S
Sci Rep; 2017 Dec; 7(1):17254. PubMed ID: 29222502
[TBL] [Abstract][Full Text] [Related]
9. Biologics: Transferrin' bispecific antibodies across the blood-brain barrier.
Bray N
Nat Rev Drug Discov; 2015 Jan; 14(1):14-5. PubMed ID: 25503335
[No Abstract] [Full Text] [Related]
10. Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core.
Clark AJ; Davis ME
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12486-91. PubMed ID: 26392563
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26.
Thom G; Burrell M; Haqqani AS; Yogi A; Lessard E; Brunette E; Delaney C; Baumann E; Callaghan D; Rodrigo N; Webster CI; Stanimirovic DB
Mol Pharm; 2018 Apr; 15(4):1420-1431. PubMed ID: 29485883
[TBL] [Abstract][Full Text] [Related]
12. VHHs as tools for therapeutic protein delivery to the central nervous system.
Wouters Y; Jaspers T; Rué L; Serneels L; De Strooper B; Dewilde M
Fluids Barriers CNS; 2022 Oct; 19(1):79. PubMed ID: 36192747
[TBL] [Abstract][Full Text] [Related]
13. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle.
Niewoehner J; Bohrmann B; Collin L; Urich E; Sade H; Maier P; Rueger P; Stracke JO; Lau W; Tissot AC; Loetscher H; Ghosh A; Freskgård PO
Neuron; 2014 Jan; 81(1):49-60. PubMed ID: 24411731
[TBL] [Abstract][Full Text] [Related]
14. Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody.
Faresjö R; Sehlin D; Syvänen S
Fluids Barriers CNS; 2023 May; 20(1):34. PubMed ID: 37170266
[TBL] [Abstract][Full Text] [Related]
15. Indium-111 radiolabelling of a brain-penetrant Aβ antibody for SPECT imaging.
Gustavsson T; Herth MM; Sehlin D; Syvänen S
Ups J Med Sci; 2024; 129():. PubMed ID: 38863725
[TBL] [Abstract][Full Text] [Related]
16. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys.
Kariolis MS; Wells RC; Getz JA; Kwan W; Mahon CS; Tong R; Kim DJ; Srivastava A; Bedard C; Henne KR; Giese T; Assimon VA; Chen X; Zhang Y; Solanoy H; Jenkins K; Sanchez PE; Kane L; Miyamoto T; Chew KS; Pizzo ME; Liang N; Calvert MEK; DeVos SL; Baskaran S; Hall S; Sweeney ZK; Thorne RG; Watts RJ; Dennis MS; Silverman AP; Zuchero YJY
Sci Transl Med; 2020 May; 12(545):. PubMed ID: 32461332
[TBL] [Abstract][Full Text] [Related]
17. Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies.
Pardridge WM
Expert Opin Biol Ther; 2016 Dec; 16(12):1455-1468. PubMed ID: 27572805
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic antibodies for brain disorders.
Paul SM
Sci Transl Med; 2011 May; 3(84):84ps20. PubMed ID: 21613621
[TBL] [Abstract][Full Text] [Related]
19. Trafficking of Gold Nanoparticles Coated with the 8D3 Anti-Transferrin Receptor Antibody at the Mouse Blood-Brain Barrier.
Cabezón I; Manich G; Martín-Venegas R; Camins A; Pelegrí C; Vilaplana J
Mol Pharm; 2015 Nov; 12(11):4137-45. PubMed ID: 26440359
[TBL] [Abstract][Full Text] [Related]
20. Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting transferrin receptor 1.
Stocki P; Szary J; Rasmussen CLM; Demydchuk M; Northall L; Logan DB; Gauhar A; Thei L; Moos T; Walsh FS; Rutkowski JL
FASEB J; 2021 Feb; 35(2):e21172. PubMed ID: 33241587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
